Danaher (DHR) July 26 weekly option implied volatility into quarter results

Go back to Danaher (DHR) July 26 weekly option implied volatility into quarter results

Danaher (DHR) PT Raised to $300 at Argus

July 24, 2024 8:57 AM EDT

Argus analyst John Eade raised the price target on Danaher (NYSE: DHR) to $300.00 while maintaining a Buy rating.

The analyst comments "Our BUY rating on Danaher Corp. (NYSE: DHR) reflects our view that Danaher is well... More

Danaher (DHR) PT Raised to $275 at BofA Securities

July 24, 2024 5:24 AM EDT

BofA Securities analyst Michael Ryskin raised the price target on Danaher (NYSE: DHR) to $275.00 (from $270.00) while maintaining a Neutral rating.

The analyst comments "Bioprocess market dynamics improved in the qtr, with most excess inventory having worked through the system and customers returning to normal... More

Danaher (DHR) PT Raised to $275 at Evercore ISI

July 23, 2024 12:02 PM EDT

Evercore ISI analyst Vijay Kumar raised the price target on Danaher (NYSE: DHR) to $275.00 (from $260.00) while maintaining a Outperform rating.

The analyst comments "Thesis Update: Relative to the questions / fears heading into 1Q print, we thought DHR checked all the boxes and the results reaffirmed the normalization thesis. The 3 most recent data points in LST have been mixed / negative (RGEN mgmt. change, A Guide cut & last weeks SRT Guide cut), which made the DHR print topical. Overall results came in slight better vs Guide (- LSD core declines vs -MSD Guide), with the... More